To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric
primary immune thrombocytopenia in patients who have not responded adequately or relapsed
after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody
and/or TPO-RA, or those in whom no other second-line treatment options are suitable.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China